{
  "pmcid": "11468343",
  "sha256": "b4864a07243ac8ccf6d66de362ed04dd11ec6312ed02a2b6dd71312723491a53",
  "timestamp_utc": "2025-11-09T22:04:01.937548+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 10.638211393869287,
    "reading_ease": 34.503922064777356,
    "word_count": 247
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Continuous Monitoring of Vital Signs on General Wards: A Randomised Controlled Trial"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "Participants were randomised to receive either continuous monitoring of vital signs or usual care"
      },
      "Participants": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Intervention": {
        "score": 2,
        "evidence": "Participants were randomised to receive either continuous monitoring of vital signs or usual care with intermittent measurements"
      },
      "Objective": {
        "score": 1,
        "evidence": "This study investigates whether continuous monitoring of vital signs improves patient outcomes compared to usual care."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was hospital mortality, measured during the hospital stay."
      },
      "Randomisation_Allocation": {
        "score": 1,
        "evidence": "Randomisation and allocation concealment methods varied across studies"
      },
      "Blinding": {
        "score": 0,
        "evidence": "blinding was not consistently reported"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "Seven RCTs with 1284 participants were included. Of these, 664 were randomised to continuous monitoring and 620 to usual care."
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "No statistically significant differences were found in hospital mortality (OR 0.95, 95% CI 0.59â€“1.53, p = 0.84)"
      },
      "Harms": {
        "score": 0,
        "evidence": "Adverse events were not consistently reported."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: PROSPERO CRD42023458656."
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: Not specified."
      }
    },
    "total_score": 13,
    "max_score": 25
  }
}